Acerta Pharma
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
121 Oyster Point Blvd Fl 4, South San Fr...Phone Number
(650) 591-2800Website
www.acerta-pharma.comRevenue
$38.9 MillionIndustry
About Acerta Pharma
Acerta Pharma, a member of the AstraZeneca Group, specializes in covalent binding technology to develop novel, highly selective therapies for cancer, particularly in the field of haematology. The company focuses on creating investigational agents that directly kill cancer cells or enhance the immune system's ability to eliminate cancer. With a commitment to addressing blood cancers with high unmet needs, Acerta Pharma aims to deliver first-in-class and best-in-class medicines. Their research and development efforts are supported by a state-of-the-art facility in the Netherlands, fostering collaborations with academic and commercial partners.Explore more
Acerta Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Acerta Pharma
Compare insights from companies similar to Acerta Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$50.7M
51-200
Private
-
1999
AO
Aram OganesianVice President, Clinical Pharmacology & Nonclinical Development
Acerta Pharma Tech Stack
A closer look at the technologies used by Acerta Pharma
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acerta Pharma
Sign Up For FreeTo access detailed company insights
Acerta Pharma, a member of the AstraZeneca Group, specializes in covalent binding technology to develop novel, highly selective therapies for cancer, particularly in the field of haematology. The company focuses on creating investigational agents that directly kill cancer cells or enhance the immune system's ability to eliminate cancer. With a comm... Read More
